
Foghorn Therapeutics (FHTX) Stock Forecast & Price Target
Foghorn Therapeutics (FHTX) Analyst Ratings
Bulls say
Foghorn Therapeutics is constructive because its selective EP300 degrader program appears to offer a better therapeutic window than dual CBP/EP300 inhibition, with preclinical models showing complete responses, tumor regression, and improved platelet preservation versus inobrodib. The company’s pivot toward wholly owned assets after discontinuing FHD-909, combined with a ~40% workforce reduction and roughly $168M of cash at Q2:26, is expected to extend cash runway into H2:29 and support development through an IND targeted for late 2027. That runway gives management time to advance a focused pipeline in multiple myeloma, DLBCL, and T cell lymphomas, while external validation from CellCentric’s 67% ORR in heavily pretreated myeloma underscores the commercial and clinical relevance of the EP300/CBP biology.
Bears say
Foghorn Therapeutics is facing a weakened investment case because FHD-909, its only clinical-stage asset, showed favorable safety and exposure but failed to deliver the efficacy needed to justify further development, implying that SMARCA2/4 synthetic lethality is not translating into a viable therapeutic strategy. The decision by Foghorn and Lilly to wind down the collaboration also removes a meaningful partnered value driver, while the company’s remaining pipeline is now entirely preclinical, with the oral I&I and EP300 assets not expected to be IND-ready until late ’27 and requiring additional capital or a partner. Although the approximately 40% workforce reduction extends runway into H2:29, the lack of clinical validation, delays in the CBP program, and heavier dependence on early-stage assets support a cautious, negative outlook.
This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Foghorn Therapeutics (FHTX) Analyst Forecast & Price Prediction
Start investing in Foghorn Therapeutics (FHTX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Foghorn Therapeutics (FHTX) Forecast
Foghorn Therapeutics (FHTX) Analyst Forecast & Price Prediction
Start investing in Foghorn Therapeutics (FHTX)
Order type
Buy in
Order amount
Est. shares
0 shares